Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Operations (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Cash from Operations data on record, last reported at 19688787.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 69.11% year-over-year to 19688787.0; the TTM value through Sep 2025 reached 61040847.0, down 65.9%, while the annual FY2024 figure was 39995742.0, 56.25% down from the prior year.
  • Cash from Operations reached 19688787.0 in Q3 2025 per CAPR's latest filing, up from 20122211.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 24046566.0 in Q1 2022 and bottomed at 20122211.0 in Q2 2025.
  • Average Cash from Operations over 5 years is 6512078.53, with a median of 6542271.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: soared 822.26% in 2022, then plummeted 407.2% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 5627583.0 in 2021, then fell by 22.65% to 6902052.0 in 2022, then plummeted by 67.98% to 11594052.0 in 2023, then dropped by 27.62% to 14796329.0 in 2024, then tumbled by 33.07% to 19688787.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 19688787.0 in Q3 2025, 20122211.0 in Q2 2025, and 6433520.0 in Q1 2025.